EVELIQURE BIOTECHNOLOGIES GMBH - TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.

PIID: 75N93020C00048Solicitation ID: HHS-NIH-NIAID-2019-1

Signed Date: Dec 31, 2025Effective Date: Sep 1, 2020End Date: Closes in 348 days

Key Details

Dollars Obligated

$11.5M

Base & All Options

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

National Institutes of Health

NAICS Code

541715 - RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Description

TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.

Contractor Information

Contractor: EVELIQURE BIOTECHNOLOGIES GMBH

UEI: ZKEJW1JEKBQ9

CAGE Code: 6311N

Location: WIEN

Similar Awards

NCI OPERATIONAL TASK ORDER, FY26-FY27

LEIDOS BIOMEDICAL RESEARCH INC

$327.1M

MD NET

LEIDOS BIOMEDICAL RESEARCH INC

$163.5M

ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2)

LEIDOS BIOMEDICAL RESEARCH INC

$141.7M

AWARD OF THE BASE TO ST. JUDE FOR CEIRR CONTRACT 75N93021C00016. THIS CONTRACT WILL SUPPORT NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (CEIRR).

ST JUDE CHILDREN'S RESEARCH HOSPITAL INC

$103.3M

DOMESTIC INDUSTRIAL BASE EXPANSION OF KEY CHEMICALS FOR ACRYLONITRILE BUTADIENE RUBBER (NBR)

ASCEND PERFORMANCE MATERIALS TEXAS INC

$87.7M

View Full Record on USASpending.gov